Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Weight-Loss pill ZT006 enters Mid-Stage trial

NCT ID NCT07230132

Disease control Sponsor: Beijing QL Biopharmaceutical Co.,Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tests whether ZT006, a daily or weekly tablet, helps overweight and obese adults lose weight when combined with diet and exercise. About 184 participants will receive either ZT006 or a placebo for 28 weeks, with some continuing for an extra 12 weeks. The main goal is to measure weight change and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ZT006
What this could lead to
If successful, this could lead to a new weight-loss medication for overweight and obese individuals.
What could go wrong
This is an early Phase 2 trial with only 184 participants, so results may not apply to everyone. The drug may cause side effects or fail to show significant weight loss compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

184 people

The number who actually took part.

Started

Dec 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

MAIN STUDY: Inclusion Criteria: * Male or female, age between 18 - 65 years (both inclusive) at the time of signing of the informed consent. * Body mass index (BMI) greater than or equal to 28 kg/m², or greater than or equal to 24 kg/m²with at least one of the comorbidities: hypertension, hyperlipidemia, pre-diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD) or obstructive sleep apnea-hypopnea syndrome (OSAHS). * Having dietary caloric restriction and increased physical activity for ≥3 months, with change in body weight (increase or decrease) no more than 5%, irrespective of medical records. Exclusion Criteria: * Type 1 or type 2 diabetes or other specific types derived from other causes * Medical history of acute or chronic pancreatitis * Medical history of cholecystitis, gallstone ≤1 cm, or history of symptomatic gallbladder diseases * Use of glucagon-like peptide-1 (GLP-1) agonist, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) or GLP-1/glucagon agonist, or triple GLP-1/GIP/glucagon agonist within 90 days before screening * HbA1c ≥ 6.5% or fasting plasma glucose ≥ 7.0 mmol/L at screening * Triglyceride ≥ 5.7 mmol/L at screening * Calcitonin ≥ 50 ng/L at screening EXTENSION PERIOD: Inclusion Criteria: * Assigned to low/medium target dose groups in the main study and having completed week 28 visit in the main study * Administration of low/medium target dose ≥ 10 times in the last two weeks in the main study Exclusion Criteria: * Participation in the dense PK sampling in the main study * BMI ≤18.5 kg/m² at week 28 visit in the main study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Overweight/obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Overweight/obesity

Contacts and locations

Locations

  • Central Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, 250000, China

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, 030001, China

  • Handan First Hospital

    Handan, Hebei, 056002, China

  • Harbin Medical University Affiliated Fourth Hospital

    Harbin, Heilongjiang, 150001, China

  • Hebei Petro China Central Hospital

    Langfang, Hebei, 065000, China

  • Huzhou Central Hospital

    Huzhou, Zhejiang, China

  • Luoyang Third People's Hospital

    Luoyang, Henan, 471002, China

  • Peking University People's Hospital

    Beijing, 100044, China

  • The First People's Hospital of Chenzhou

    Chenzhou, Hunan, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 210003, China

  • Xi'an Daxing Hospital

    Xi’an, Shanxi, 710000, China

  • YueYang People's Hospital

    Yueyang, Hunan, 414022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.